Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
EternaGen / BPC 004-012Peptide · Research use only
BPC 157
$90CAD
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
BPC 157, clearly explained.
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Overview
Researchers are interested in how BPC 157 behaves in models of tissue repair, tendon injury and wound response. Almost all of that work has been done in cells and animals, so we still do not know whether the same effects occur in people.
BPC 157 is a synthetic 15-amino-acid peptide. Most published research is made up of cell, tissue and animal experiments rather than adequately controlled human trials.- Format
- Vial
- Available strengths
- 10mg
- Batch
- BPC 004-012
- Purity
- 99.2%
Research at a glancePreclinical evidence; human efficacy not established
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- GEPPPGKPADDAGLV
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.56 g/mol
- Storage and handling
- Store lyophilized material according to the conditions stated on the batch record. Protect from light and moisture.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- BPC 004-012
- Purity
- 99.2%
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Tendon and connective-tissue models
Rat tendon-transection and cultured-tendocyte studies report changes in biomechanical recovery, cell migration and stress survival.
Evidence so far: Animal and laboratory modelsQuestion 02
Wound-response pathways
Preclinical papers explore angiogenesis, fibroblast activity and nitric-oxide-related signalling after experimentally induced injury.
Evidence so far: Hypothesis-generating evidenceQuestion 03
Human outcomes
Robust randomized human evidence for musculoskeletal recovery, gastrointestinal disease or systemic use has not been established.
Evidence so far: Major evidence gapProposed mechanism
How researchers are investigating the mechanism.
Experimental work has examined cell migration, survival under oxidative stress and signalling involving focal adhesion kinase and paxillin. These are mechanistic observations, not proof of healing or recovery in people.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Transected Achilles tendon in rats with in-vitro tendocyte experiments
- What researchers saw
- Investigators reported improved tendon measures and changes in tendocyte growth under the study conditions.
- Why that is not the whole story
- A rat injury model cannot establish clinical benefit, dose, route or safety in humans.
Study 02FDA review of BPC-157-related bulk substances
- What researchers saw
- FDA identified limited safety information plus potential immunogenicity and peptide-impurity concerns.
- Why that is not the whole story
- A purity percentage does not resolve route-specific safety, immunogenicity or human-efficacy gaps.
Evidence gaps
What remains unknown?
- No established therapeutic indication or adequately characterized benefit-risk profile for human use.
- Human pharmacokinetics, route-specific safety and long-term adverse effects remain insufficiently characterized.
- Findings from one experimental formulation cannot authenticate or predict the performance of a separately sourced material.
Primary sources
Check the original sources.
- Primary preclinical studyStaresinic et al. Rat Achilles tendon and tendocyte study. J Orthop Res. 2003. PMID 14554208.
- Regulatory safety reviewU.S. FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks: BPC-157.
- Canadian public advisoryHealth Canada. Think twice before injecting peptides bought online. 9 April 2026.
Related products
Continue comparing.
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity
Peptide · Vial
Verified recordTesamorelin
$11010mg
A synthetic peptide that mimics a natural signal involved in the release of growth hormone.
Current batchTESA 003-040
Published result99.4% reported purity